{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T01:32:44Z","timestamp":1724895164735},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40487-020-00114-4","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T15:02:18Z","timestamp":1588431738000},"page":"59-66","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location"],"prefix":"10.1007","volume":"8","author":[{"given":"Daniel","family":"Rosas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E.","family":"Raez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"issue":"2","key":"114_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non\u2013small-cell lung cancer. N Engl J Med. 2002;346(2):92\u20138.","journal-title":"N Engl J Med."},{"key":"114_CR2","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm560040.htm. Accessed 11 Apr 2019."},{"issue":"1","key":"114_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40880-018-0274-3","volume":"38","author":"L Yan","year":"2018","unstructured":"Yan L, Zhang W. Precision medicine becomes reality\u2014tumor type-agnostic therapy. Cancer Commun. 2018;38(1):6.","journal-title":"Cancer Commun."},{"key":"114_CR4","unstructured":"National Institutes of Health (NIH) ClinicalTrials.gov. A study to test the safety of the investigational drug selitrectinib in children and adults that may treat cancer. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03215511?cond=LOXO-195&rank=1. Accessed 11 Apr 2019."},{"key":"114_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2353\/jmoldx.2006.050092","volume":"8","author":"KM Murphy","year":"2006","unstructured":"Murphy KM, Zhang S, Geiger T, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite in\u2014stability in colorectal cancers. J Mol Diagn. 2006;8:305\u201311.","journal-title":"J Mol Diagn."},{"key":"114_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703\u201313.","journal-title":"Nat Med."},{"key":"114_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"114_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u201330.","journal-title":"J Clin Oncol."},{"key":"114_CR9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","volume":"33","author":"SN Gettinger","year":"2015","unstructured":"Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-pro-grammed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004\u2013122.","journal-title":"J Clin Oncol."},{"key":"114_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","volume":"130","author":"JP Ward","year":"2016","unstructured":"Ward JP, Gubin MM, Schreiber RD. The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol. 2016;130:25\u201374.","journal-title":"Adv Immunol."},{"key":"114_CR11","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1002\/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U","volume":"91","author":"TC Smyrk","year":"2001","unstructured":"Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417\u201322.","journal-title":"Cancer"},{"issue":"26","key":"114_CR12","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med."},{"key":"114_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8:836\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0338.","journal-title":"Cancer Discov."},{"key":"114_CR14","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","volume":"81","author":"AY Li","year":"2019","unstructured":"Li AY, McCusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019;81:101911.","journal-title":"Cancer Treat Rev."},{"issue":"6892","key":"114_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2012","unstructured":"Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2012;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"1","key":"114_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.gde.2006.12.005","volume":"17","author":"N Dhomen","year":"2007","unstructured":"Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev. 2007;17(1):31\u20139.","journal-title":"Curr Opin Genet Dev."},{"issue":"1","key":"114_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1182\/blood-2011-08-371179","volume":"119","author":"E Tiacci","year":"2012","unstructured":"Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119(1):192\u20135.","journal-title":"Blood"},{"issue":"3","key":"114_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cncr.27782","volume":"119","author":"RN Grisham","year":"2013","unstructured":"Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013;119(3):548\u201354.","journal-title":"Cancer"},{"issue":"14","key":"114_CR19","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","volume":"119","author":"L Xi","year":"2012","unstructured":"Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34\u2014expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14):3330\u20132.","journal-title":"Blood"},{"issue":"26","key":"114_CR20","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","volume":"29","author":"A Marchetti","year":"2011","unstructured":"Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574\u20139.","journal-title":"J Clin Oncol."},{"issue":"14","key":"114_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"M Xing","year":"2013","unstructured":"Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493\u2013501.","journal-title":"JAMA"},{"issue":"3","key":"114_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"AD Roth","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, and SAKK 60\u201300 trial. J Clin Oncol. 2010;28(3):466\u201374.","journal-title":"J Clin Oncol."},{"issue":"9839","key":"114_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomized controlled trial. Lancet. 2012;380(9839):358\u201365.","journal-title":"Lancet"},{"issue":"26","key":"114_CR24","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med."},{"issue":"5","key":"114_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Aet al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315.","journal-title":"Lancet Oncol."},{"key":"114_CR26","unstructured":"A study of repotrectinib (TPX-0005) in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 Rearrangements- ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03093116?cond=TPX-0005&rank=1. Accessed 24 Apr 2020."},{"key":"114_CR27","unstructured":"A phase I\/IIa open-label, dose escalation and cohort expansion trial of oral TSR-011 in patients with advanced solid tumors and lymphomas - Full Text View - ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02048488?cond=TSR-011. Accessed 24 Apr 2020."},{"key":"114_CR28","unstructured":"Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors-ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02675491?cond=DS-6051b. Accessed 24 Apr 2020."},{"key":"114_CR29","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1158\/1078-0432.CCR-08-1815","volume":"15","author":"GM Brodeur","year":"2009","unstructured":"Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15:3244\u201350.","journal-title":"Clin Cancer Res."},{"key":"114_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.lungcan.2012.07.011","volume":"78","author":"K Okamura","year":"2012","unstructured":"Okamura K, Harada T, Wang S, et al. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;78:100\u20136.","journal-title":"Lung Cancer."},{"issue":"8","key":"114_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion\u2014positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med."},{"key":"114_CR32","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2147\/TCRM.S147381","volume":"14","author":"D Liu","year":"2018","unstructured":"Liu D, Offin M, Harnicar S, Li BT, Drilon A. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. TCRM. 2018;14:1247\u201352.","journal-title":"TCRM."},{"key":"114_CR33","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.molonc.2014.06.001","volume":"8","author":"E Ardini","year":"2014","unstructured":"Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8:1495\u2013507.","journal-title":"Mol Oncol."},{"key":"114_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0590-1","author":"S Kummar","year":"2018","unstructured":"Kummar S, Lassen U. TRK inhibition\u2014a new tumor-agnostic treatment strategy. Targ Oncol. 2018. https:\/\/doi.org\/10.1007\/s11523-018-0590-1.","journal-title":"Targ Oncol."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-020-00114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-020-00114-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-020-00114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:02:00Z","timestamp":1724457720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-020-00114-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["114"],"URL":"https:\/\/doi.org\/10.1007\/s40487-020-00114-4","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2020,5,2]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}